Impressive Sales Growth from Novonesis
Novonesis has impressively reported an 8% organic sales growth in the first nine months, heightening optimism among stakeholders. The company's upward revision of its full-year outlook, now targeting a growth of 7-8%, demonstrates a sound response to market conditions and strategic execution.
CEO Ester Baiget's Confidence
Ester Baiget, the President and CEO of Novonesis, expressed satisfaction with the company's recent performance, highlighting solid profitability across its sales areas. Despite facing notable currency headwinds, the company achieved an adjusted EBITDA margin of 37.3%. Baiget remarked on the resilience of the business model, stating, "Our performance was strong across all sales areas and in emerging and developed markets."
Performance Highlights of the First Nine Months
In the latest performance figures, Novonesis showcased broad-based growth:
Sales Growth Breakdown
The reported 8% organic sales growth included a ~1 percentage point decline due to exiting certain markets. Price contributions remained consistent from the previous quarter, accounting for another ~1 percentage point. Key sectors, such as Food & Health, noted a 9% growth, while Planetary Health achieved 8% organic sales growth.
Market Segment Performance
Emerging Markets displayed an impressive 12% organic sales growth, while Developed Markets contributed 6%. These figures indicate Novonesis' ability to adapt to various market environments, ensuring consistent growth.
Financial Metrics
Financial health appeared robust through the nine-month results:
Profitability Metrics
With an adjusted EBITDA margin at 37.3%, up from 37.1% in the previous quarter, the company's adjusted net profit surged by 22%. Free cash flow before acquisitions reached EUR 668.4 million, reflecting strong financial management amidst operational challenges.
Outlook for 2025
Novonesis has slightly adjusted its organic sales growth expectation for 2025, now estimated between 7-8%. The company aims to sustain mid-single-digit organic growth into the fourth quarter and expects its adjusted EBITDA margin to remain within the lower end of the forecasted range of 37-38%. The anticipated growth excludes the impact of exiting certain countries.
Ongoing Strategic Priorities
Novonesis continues to execute its strategic priorities, guiding the company’s long-term vision towards its 2030 targets. The commitment to robust growth in emerging sectors underlines its adaptability and resilience, positioning the company favorably in a competitive market.
Media Contact Information
If you'd like to learn more about Novonesis, please reach out to their media relations team:
Magnus Højberg Mernild
Senior Media Relation Manager
email: media-relations@novozymes.com
Phone: +45 51 71 78 30
Tobias Cornelius Bjorklund
Head of Investor Relations
email: tobb@novonesis.com
Frequently Asked Questions
What recent financial growth has Novonesis reported?
Novonesis reported an 8% organic sales growth in the first nine months.
What is the revised growth outlook for Novonesis in 2025?
The full-year outlook for organic sales growth is now between 7-8%.
How did CEO Ester Baiget describe Novonesis' performance?
Baiget expressed satisfaction with the profitability and resilience of the business despite market challenges.
What financial metrics are highlighted in Novonesis' report?
Notable metrics include a 37.3% adjusted EBITDA margin and a 22% increase in adjusted net profit.
How is Novonesis positioning itself for the future?
Novonesis is focusing on executing its strategic priorities to meet its 2030 targets while maintaining growth across emerging markets.
